Dutasteride vs Finasteride for Male Pattern Hair Loss

Both drugs stop testosterone converting into DHT, the androgen behind follicle miniaturisation in male pattern hair loss. The split is which enzyme they switch off. The FDA label for finasteride describes it as an inhibitor of the type II isoform, which handles the bulk of that conversion in reproductive tissue. The dutasteride label describes a competitive inhibitor of both the type 1 and type 2 isoenzymes, and notes the type 1 form also converts testosterone in skin and in the liver.

That second enzyme is the entire argument. Your balding scalp is skin, and skin runs type 1 alongside type 2, so a dual blocker reaches conversion finasteride leaves running. Neither molecule binds the androgen receptor, so this is a hormone supply problem rather than a signaling one. Whether the extra suppression turns into hair you can actually see in a mirror is a separate question, and the trial answer is a good deal narrower than the pharmacology makes it sound.

The pharmacodynamics are not close. The finasteride label reports roughly 65% serum DHT suppression within 24 hours of a 1 mg tablet. The dutasteride label reports median serum DHT down 85% after one week and 90% after two on 0.5 mg daily, holding between 93% and 95% out to four years. A dose ranging trial in 399 men with enlarged prostates measured a 94.7% mean DHT decrease on dutasteride 0.5 mg against 70.8% on finasteride 5 mg, and with far less variation between one man and the next.

Hair counts move less than that gap implies. In the pivotal finasteride trials, men on 1 mg daily finished 12 months with 107 more hairs than placebo inside a one inch circle, widening to 138 hairs at two years and 277 at five. At the 12 month mark, 14% of the finasteride group had lost ground from baseline against 58% on placebo.

Those remain the only five year hair count figures in any US label, and dutasteride has nothing equivalent to set beside them.

This is the fact most comparisons skate past. The finasteride 1 mg label carries an indication for male pattern hair loss in men, and states efficacy in bitemporal recession was never established. The US dutasteride label carries a single indication, symptomatic benign prostatic hyperplasia. Nothing on it mentions hair. Every American prescription of dutasteride for a receding hairline is off label, which a clinician may legally write, and which is not the same thing as unstudied.

Elsewhere it is a hair drug outright. Korean regulators approved dutasteride 0.5 mg for androgenetic alopecia in men in 2009, and a 2022 review notes that Japan and South Korea have both approved oral dutasteride 0.5 mg daily for male pattern hair loss. That approval is why five year Korean follow up exists while the US has none. If you want evidence stretching past 24 weeks, it was written under another regulator, in another language, on another continent.

A 5-alpha-reductase inhibitor and minoxidil are not rivals. Minoxidil lengthens the growth phase and does nothing to DHT, so most scalp plans run one of each rather than picking between them. A 2022 review of oral minoxidil, finasteride and dutasteride placed a probable efficacy ranking of dutasteride 0.5 mg first, then finasteride 5 mg, then minoxidil 5 mg, then finasteride 1 mg. Rankings assembled across separate trials carry real uncertainty, so read that as a hypothesis rather than a settled result.

The counterweight sits in the same literature. A 2014 network meta-analysis of randomized trials of finasteride 1 mg, finasteride 5 mg and dutasteride 0.5 mg found the active treatments were not significantly different from each other on efficacy, nor significantly different from placebo on global sexual dysfunction. Two competent reads of the same evidence disagree, and that is the honest state of the question. It is also why anyone naming a winner before asking about your goals is guessing at your expense.

The dosing itself is simple. Finasteride is one 1 mg tablet daily, and its label says three months or more of daily use is generally needed before benefit shows. Dutasteride for hair is written at the 0.5 mg capsule strength, the same one used in the 24 week trial that ran 0.02 mg, 0.1 mg and 0.5 mg against finasteride 1 mg in 917 men aged 20 to 50. Some prescribers space dutasteride to two or three capsules a week, which the long half life makes coherent even though no label describes it.

Half life is where these two stop resembling each other. The finasteride label puts mean terminal half life at about 5 to 6 hours in men aged 18 to 60. The dutasteride label puts it near 5 weeks at steady state, hitting 65% of steady state after a month and around 90% after three, with serum levels still detectable four to six months after the final dose.

Coming off finasteride is a decision you can unwind in a day. Coming off dutasteride takes most of a season.

Start with what the controlled trials logged. In the finasteride hair loss studies, year one rates were 1.8% decreased libido, 1.3% erectile dysfunction and 1.2% ejaculation disorder, against 1.3%, 0.7% and 0.7% on placebo, each falling to 0.3% or lower by year five. The dutasteride prostate trials logged 4.7% impotence and 3.0% decreased libido in the months 0 to 6 window, against 1.7% and 1.4% on placebo, falling to 1.4% and 0.7% over months 7 to 12. Resist reading that as three times worse. The windows are not the same: the finasteride figures cover a full first year, the dutasteride figures the first six months. Those men also averaged 66 years old with prostate disease, and both labels warn rates from separate trials do not compare directly.

The genuine dispute is about symptoms that outlast the tablet. The finasteride label lists sexual dysfunction continuing after discontinuation, plus depression and suicidal ideation, among post-marketing reports where frequency cannot be estimated and causation is not established. A 2016 systematic review found sexual effects reported in 3.4% to 15.8% of men and no direct link to depression at that time, while a 2026 review reports pharmacovigilance data have since strengthened that association. Reported experience is real. A settled causal mechanism is not. Raise it before you start.

Both drugs quietly distort prostate cancer screening. The dutasteride label states serum PSA falls roughly 50% within three to six months, and that an isolated reading should be doubled before comparison with untreated men. At the 1 mg hair dose, the finasteride label reports mean PSA falling from 0.7 to 0.5 ng/mL over 12 months, and the 5 mg label reports about 50% within six months under the same doubling rule. Both labels also record Gleason 8 to 10 cancers at 1.8% on finasteride 5 mg against 1.1% on placebo, and 1% against 0.5% for dutasteride.

Two housekeeping rules get missed constantly. The dutasteride label instructs men not to donate blood until at least six months after the last dose, so no transfusion delivers the drug to a pregnant recipient. Neither finasteride label carries that instruction. On handling, dutasteride is a soft gelatin capsule that can be absorbed through skin if it leaks, and women who are or may be pregnant should not handle it, whereas finasteride tablets are film coated and block contact unless broken or crushed.

Finasteride is among the most commonly written drugs in online men's health, and an asynchronous questionnaire visit is the normal route to it. Dutasteride differs in one specific way. You are asking a clinician to prescribe outside the FDA label for a cosmetic indication, and a fair number will decline. That is not obstruction. It is a prescriber carrying liability for a use their own regulator never reviewed, and a service that agrees in ninety seconds without asking why finasteride failed you is worth less for it.

Be ready for real questions. Whether anyone in your household is pregnant or trying to conceive changes the handling conversation, and it changes it more for capsules than for coated tablets. Your age and any family history of prostate cancer decide whether a baseline PSA belongs before you start rather than after. A platform that never raises PSA, blood donation or pregnancy exposure is running a checkout and calling it a consult. That judgment belongs to whoever signs the prescription, and none of this is medical advice.

Both molecules are generic and cost almost nothing to buy. In the CMS National Average Drug Acquisition Cost file published on 2 September 2026, generic finasteride 1 mg sits at about $0.043 a tablet and generic dutasteride 0.5 mg at about $0.161 a capsule. Over thirty days that is roughly $1.28 against $4.82. NADAC is what a pharmacy pays to acquire the drug rather than a retail price, so treat those figures as the floor underneath every number you are ever quoted. The same file carries two brand Propecia 1 mg listings, at $3.58511 and $3.96500 a tablet, which is 84 to 93 times the generic of an identical molecule. What a telehealth service charges you is mostly the visit, the platform and the shipping, not the pills. Dutasteride runs dearer than finasteride at acquisition, but that gap is trivial next to the gap between a generic filled locally and a branded subscription.

Ask any service to quote the drug cost separately from the membership fee.

Criteria beat brand names here. A prescriber worth paying will ask how long you ran finasteride and at what dose before entertaining dutasteride, because escalating after eight weeks tells nobody anything. They will say plainly that dutasteride for hair is off label in the US and spell out what that means for you. They will set a baseline PSA if your age warrants one, and put it in writing. And they will describe their stopping plan before you ever start.

The half life question is the sharpest filter you have. Ask what happens if a sexual side effect turns up three months in. With finasteride the answer is that you stop and blood levels clear inside a day. With dutasteride the drug stays measurable for four to six months, so the honest answer involves waiting it out. A service that cannot describe that difference has not thought about your downside. There is no winner here, only how much suppression you want against how much reversibility you need.